Tamara Restel, Agnieszka Szkudlarek, Małgorzata Maciążek-Jurczyk
In vitro studies of piracetam inhibitory properties in the glycation of human serum albumin process
2024-12-02
Subject of the study. As a major plasma blood protein, human serum albumin (HSA) is responsible for many key processes in the body. Structural modifications that may be caused by increased glycation process in diabetes, can affect the serum albumin stability, activity and binding with drugs capacity. Advanced glycation end products (AGEs) have a negative impact on efficiency and functioning of many systems and organs. Piracetam (PIR) is a cyclic compound derived from gamma-aminobutyric acid (GABA), showing beneficial effects on impaired brain activities by improving cognitive and neuronal functions. PIR is used in cases of brain hypoxia resulting from an accident, for example, in elderly people struggling with Alzheimer’s disease, and in children with dyslexia disease.
The goal of the study. The goal of the study was to analyse the conformational changes occurring in the modified (glycated) structure of HSA and PIR inhibitory properties on the course of HSA glycation.
Materials and methods. The present studies were conducted using glucose-glycated human serum albumin (gHSAGLC), glucose-glycated human serum albumin in the presence of piracetam (gHSAGLC-PIR) and unmodified human serum albumin. Spectrofluorescence, spectroscopy UV-Vis and far-UV circular dichroism (CD) techniques have been used.
Results. HSA conformational changes were analyzed using emission spectra, absorption spectra and their second derivatives, synchronous spectra, excited spectra, Red Edge Excitation Shift (REES) effect and far-UV circular dichroism spectra. In addition, the formation of HSA AGEs was compared.
Conclusions. The glycation process probably affected the HSA tertiary structure, resulting in changes in the tryptophanyl residue (Trp-214) and tyrosyl (Tyrs) residues. Furthermore, it has been proven that PIR can be an effective inhibitor of the glycation HSA process in diabetics.
Keywords: human serum albumin (HSA), glycation, piracetam (PIR), spectroscopic techniques.
© Farm Pol, 2024, 80(7): 459–467
In vitro studies of piracetam inhibitory properties in the glycation of human serum albumin process